Safety and Tolerability of Neoadjuvant Sunitinib in HCC
Thomas Marron, PhD, MD, discusses the safety and tolerability of neoadjuvant sunitinib in hepatocellular carcinoma.
Thomas Marron, PhD, MD, assistant director of early phase and immunotherapy clinical trials at the Tisch Cancer Institute and assistant professor of Medicine at the Icahn School of Medicine at Mount Sinai discusses the safety and tolerability of neoadjuvant sunitinib (Sutent) inhepatocellular carcinoma (HCC).
According to Marron, of the 21 patients who received sunitinib prior to surgery with curative intent, all 21 made it to the operating room (OR). Of those 21 patients, 20 made it with no issue and 1 developed pneumonitis. Overall, it was a well-tolerated treatment.
There has to be balance between efficacy and tolerability, according to Marron. The sunitinib regimen was a relatively short, easy treatment that did not significantly delay the patient’s curative intent therapy.
The findings suggest that in the future, single-cell sequencing will allow investigators to look at T cells, especially the ones that are tumor specific, according to Marron. These cells may not only help inform further iterations of neoadjuvant trials but also future combination therapies.
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
FDA Accepts NDA Resubmission of Rivoceranib and Camrelizumab in HCC
October 21st 2024The new drug application resubmission of rivoceranib/camrelizumab in the first line in unresectable or metastatic hepatocellular carcinoma is supported by the final survival analysis of CARES-310 trial.
Read More
FDA Receives Resubmitted NDA for Camrelizumab/Rivoceranib Combo in Unresectable HCC
September 24th 2024A new drug application has been resubmitted to the FDA for the combination of camrelizumab and rivoceranib as a first-line treatment for unresectable hepatocellular carcinoma, following a complete response letter in May 2024.
Read More
